Molecular Formula | C38H48Cl2N4O4S |
Molar Mass | 727.78 |
Density | 1.23 |
Storage Condition | -20℃ |
In vitro study | RG7112 is a potent and selective MDM2 antagonist, a member of the Nutlin family, and is currently in Phase I clinical studies. RG7112 binds MDM2 with high affinity (K D of 10.7 nM), blocking its interaction with p53 in vitro. The crystal structure of the RG7112-MDM2 complex indicates that the small molecule binds to the p53 pocket of MDM2, mimicking the interaction of important p53 amino acid residues. Treatment of cancer cells expressing wild-type p53 by RG7112 activates the p53 pathway, leading to cell cycle arrest and apoptosis. RG7112 exhibited potent anti-tumor activity against a panel of tumor cell lines. However, their anti-apoptotic activity was quite different, with optimal responses observed in MDM2 gene-amplified osteosarcoma cells. |
In vivo study | RG7112 activates the p53 pathway in vivo and induces tumor cell apoptosis. Oral administration of RG7112 to human xenograft-bearing mice at nontoxic concentrations caused dose-dependent changes in proliferation/apoptosis biomarkers, as well as tumor suppression and regression. Notably, RG7112 was highly synergistic with chemical castration in LNCaP xenograft tumors. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.374 ml | 6.87 ml | 13.74 ml |
5 mM | 0.275 ml | 1.374 ml | 2.748 ml |
10 mM | 0.137 ml | 0.687 ml | 1.374 ml |
5 mM | 0.027 ml | 0.137 ml | 0.275 ml |